Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, freezing gamma-irradiated amniotic fluid increased hair follicles and accelerated the transition to the anagen stage in rats, suggesting potential for treating hair loss safely and effectively.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This case report highlights the importance of considering frontal fibrosing alopecia in young women, emphasizing early diagnosis to preserve hair and limit inflammation.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

In this study, injectable platelet-rich fibrin (i-PRF) was found to enhance the proliferative, migratory, and hair-inducing abilities of dermal papilla cells more effectively than platelet-rich plasma through the TGF-β/Smad pathway.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

In this study, the KPAI and KP-IGA scoring systems for assessing keratosis pilaris showed excellent interrater and intrarater reliability, offering standardized measures for clinical and research use.

This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

In this case-control study, researchers observed that women with female pattern hair loss exhibited significantly lower serum IGF-1 levels than controls, while IGFBP-3 levels showed no significant difference, suggesting a potential role for IGF-1 in the condition.

This announcement explains the Fellow designation for hair restoration surgeons meeting specific educational criteria, without reporting new research findings.

Early diagnosis of frontal fibrosing alopecia is crucial to prevent permanent hair loss.

This study found that combining plasma rich in growth factors with conventional treatment significantly improved hair regrowth and reduced symptoms in patients with frontal fibrosing alopecia compared to conventional treatment alone.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This article explores the potential of platelet-rich fibrin therapies for androgenetic alopecia and highlights their possible advantages over traditional treatments without reporting new clinical results.

In this study, the researchers developed a computer-aided imaging system to quantitatively measure baldness in Chinese women with female pattern hair loss, potentially improving the precision of severity evaluation compared to traditional scales.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

The FDA approved a new Pfizer drug for hair loss in teens.

This study found that women with female pattern hair loss had significantly lower serum IGF-1 levels compared to controls, but no significant association between IGFBP-3 levels and hair loss severity was observed.

This review found that intralesional corticosteroid injections and 5-alpha-reductase inhibitors were reported as the most effective treatments for frontal fibrosing alopecia, with oral isotretinoin showing promise for facial papule improvement.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.

This study found that targeting both hormonal and immune pathways improved treatment outcomes in androgenetic alopecia patients with an under-recognized inflammatory component called PIILIF, which may contribute to treatment resistance.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.